A Phase II, Open-Label, Multicenter Study to Evaluate the Effect of Tumor-Based HER2 Activation on the Efficacy of rhuMAb 2C4 (Pertuzumab) in Subjects With Recurrent Non-Small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 18 Jun 2015
At a glance
- Drugs Pertuzumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Genentech
- 10 Jun 2017 Biomarkers information updated
- 24 Aug 2008 Actual end date (Dec 2004) added as reported by ClinicalTrials.gov.
- 24 Sep 2005 New trial record.